Pharma Update
Susvimo: Continuous 6m delivery preferred by 93% patients vs IVT
Commercial US relaunch expected in 2024 and ex-US 2025+
Stronger vision outcomes
with potential for extended ≥Q6M dosing
Continuous
delivery of aVEGF
via PD implant
1-2
refill exchanges
per year
•
93% of patients prefer Susvimo to IVT injections¹
Prefer IVT
No Preference
Prefer PDS
Roche
SuSvim o™
ranibizumab injection F
180mg/ml.
Ongoing development for the Port Delivery Platform
October 2022: SUSVIMO voluntarily recalled due to manufacturing
variability; root cause identified and progress made to implement
technical solution
February 2023: Positive data from pivotal Ph III studies in DME
(PAGODA) and DR (PAVILLION) presented at Angiogenesis:
•
DME: Improved vision (Q6M dosing)²
DR: Superior improvement in ≥ 2-Step ETDRS-DRSS (Q9M
dosing)³
Trend toward improved safety profile with evolved
surgical implantation training and technique²,3
• Q4 2023: Clinical trials expected to restart
•
Ph lllb (VELODROME) assessing Q9M dosing in nAMD
First trials of next generation bispecifics (DutaFabs)
1. Holekamp N et al. ARCHWAY Ph III Trial of the PDS for nAMD, American Academy of Ophthalmology, 129(3), 2022; 2. Campochiaro P et al. Port Delivery System With Ranibizumab in Diabetic Macular Edema: Primary Analysis Results of the Ph III PAGODA Trial, Presented at the
Macula Society 46th Annual Meeting, Miami, FL, February 15-18, 2023. 3. Holekamp N et al. Port Delivery System With Ranibizumab in the Treatment of Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema: Primary Analysis Results of the Ph III PAVILION Trial,
Presented at the Macula Society 46th Annual Meeting, Miami, FL, February 15-18, 2023. VEGF = Vascular Endothelial Growth Factor; Q6M-every 6 months; PD = Port Delivery; IVT-intravitreal injection; DME-diabetic macular edema; DR-diabetic retinopathy; EDTRDS-DRSS-early
treatment diabetic retinopathy study-diabetic retinopathy severity scale; Q9M-every 9 months; nAMD = neovascular age related macular degeneration;
50
50View entire presentation